HedgeChatter

  • Home /
  • Tag Archives

GEVA

Synageva BioPharmaâ„¢ to Present at the Cowen and Company Health Care Conference

[Business Wire] – Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, today announced its presentation at the upcoming C moreView todays social media effects on GEVAView the latest stocks trending across Twitter. Click to view dashboardSee who Synageva is hiring next, click here to view […]

February 21, 2014 Bystocknews , Comments Off on Synageva BioPharmaâ„¢ to Present at the Cowen and Company Health Care Conference read more

Synageva BioPharmaâ„¢ to Host 2013 Fourth Quarter and Full Year Financial Results Conference Call on March 3

[Business Wire] – Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, will report 2013 fourth quarter and full year financial results after the NASDAQ Market closes on Monday, March 3, 2014. moreView todays social media effects on GEVAView the latest stocks trending across Twitter. Click to view dashboardSee who Synageva is hiring next, click here […]

February 18, 2014 Bystocknews , Comments Off on Synageva BioPharmaâ„¢ to Host 2013 Fourth Quarter and Full Year Financial Results Conference Call on March 3 read more

Synageva BioPharmaâ„¢ Highlights Sebelipase Alfa and LAL Deficiency Data at the Lysosomal Disease Network (LDN) WORLD Symposiumâ„¢

[Business Wire] – Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, today announced sebelipase alfa and lysosomal acid moreView todays social media effects on GEVAView the latest stocks trending across Twitter. Click to view dashboardSee who Synageva is hiring next, click here to view […]

February 13, 2014 Bystocknews , Comments Off on Synageva BioPharmaâ„¢ Highlights Sebelipase Alfa and LAL Deficiency Data at the Lysosomal Disease Network (LDN) WORLD Symposiumâ„¢ read more

4:09 pm Synageva Biopharma highlights SBC-103 Data at the Lysosomal Disease Network (:LDN) WORLD Symposium; SBC-103 preclinical data confirms results from previous studies, describes a potential mechanism for central nervous system uptake,

moreView todays social media effects on GEVAView the latest stocks trending across Twitter. Click to view dashboardSee who Synageva is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on 4:09 pm Synageva Biopharma highlights SBC-103 Data at the Lysosomal Disease Network (:LDN) WORLD Symposium; SBC-103 preclinical data confirms results from previous studies, describes a potential mechanism for central nervous system uptake, read more

Synageva BioPharmaâ„¢ Highlights SBC-103 Data at the Lysosomal Disease Network (LDN) WORLD Symposiumâ„¢

[Business Wire] – Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, today announced SBC-103 data from an oral and poster presentation at the LDN WORLD Symposium being held February 11-13 in San Dieg moreView todays social media effects on GEVAView the latest stocks trending across Twitter. Click to view dashboardSee who Synageva is hiring next, […]

February 12, 2014 Bystocknews , Comments Off on Synageva BioPharmaâ„¢ Highlights SBC-103 Data at the Lysosomal Disease Network (LDN) WORLD Symposiumâ„¢ read more